15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Neurogene Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $65.00 to $166.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $104.00 sits 173% above the current $38.13. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.37 next quarter toward $-5.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Neurogene Inc.
As of Sep, 4 of 4 firms rate NGNE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NGNE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.37
Range $-1.50 – $-1.20 · 4 analysts · +21% YoY
Next period, 4 analysts expect Neurogene Inc to earn $-1.37 a share (range $-1.50 – $-1.20), versus $-1.13 a year earlier. Full-year consensus is $-5.66, growing to $-5.18 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Neurogene Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NGNE.
#1
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$81.00+112.4% to target
Overall win rate
44%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$65.00+70.5% to target
Overall win rate
34%
+ Follow
#3
WI
Whitney Ijem
Canaccord Genuity · Rank #350
Buy
$166.00+335.4% to target
Overall win rate
32%
+ Follow
#4
Sami Corwin
William Blair
Buy
No targeton NGNE
Coverage
—
+ Follow
#5
PD
Patrick Dolezal
LifeSci Capital
Buy
$63.00+65.2% to target
Coverage
—
+ Follow
NGNE stock forecast FAQ
What is NGNE's average 12-month price target?+
The 3 analysts with a live target average $104.00 for Neurogene Inc over the next 12 months, ranging from a $166.00 high to a $65.00 low.
Is NGNE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NGNE?+
The Street-high target is $166.00 (Canaccord Genuity), and the Street-low is $65.00 (HC Wainwright & Co.). The average of all 3 active targets is $104.00.
How many Wall Street analysts cover NGNE?+
4 analysts have an active rating on Neurogene Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering NGNE?+
Among analysts who currently cover NGNE, Debjit Chattopadhyay of Guggenheim has the strongest overall Quantellect track record (Rank #113). Their current call is Buy with a $81.00 target.
What is Neurogene Inc's projected EPS for next quarter?+
The consensus estimate is $-1.37 per share (range $-1.50 – $-1.20) across 4 analysts. Full-year EPS is projected at $-5.66, rising to $-5.18 the following year.
How much revenue is Neurogene Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NGNE lately?+
As of Sep, 4 of 4 firms rate NGNE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NGNE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
